Clinical Trials

20 enrolled

Phase 2 Not yet recruiting

SCLC

NCT07405086 2026-02-12

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

160 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT06610734 2026-02-09

SKY

202 enrolled

Small Cell Lung Cancer Extensive Stage

NCT07171606 2025-12-18

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients

240 enrolled

Phase 2 Not yet recruiting

First-line Advanced NSCLC Patients

NCT07271602 2025-12-09

A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.

104 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05440916 2025-12-02

PRIMM

50 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05846646 2025-10-20

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

Phase 2 Terminated

6 enrolled 7 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

NCT05509699 2025-08-29

Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

21 enrolled

Small Cell Lung Carcinoma

NCT06947694 2025-07-22

A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases

427 enrolled

NSCLC Stage IV Without EGFR/ALK Mutation

NCT06977074 2025-05-23

PROPHET

83 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04997382 2025-02-25

CLASSIC5

112 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06751849 2024-12-30

Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment

10 enrolled

Advanced NSCLC

NCT06751901 2024-12-30

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment

10 enrolled

Advanced NSCLC

NCT06388031 2024-11-07

ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI

27 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05014464 2024-09-20

ATPase

90 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04322578 2024-06-04

CONFIRM

120 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03511391 2024-01-23

CHEERS

DermatologicGenitourinaryHead & NeckThoracic

99 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

441 enrolled

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT04459078 2022-12-02

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

63 enrolled

Adenocarcinoma of Lung

NCT05603013 2022-11-02

Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)

45 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05520853 2022-08-30

SBRT Combined With PD-1 Inhibitor and Thoracic Hyperthermia for Advanced NSCLC

63 enrolled

Hyperthermia, Carcinoma, Non-Small-Cell Lung

NCT05392686 2022-05-26

PD1 and PARP for Maintenance Therapy in NSLLC

52 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT04613804 2020-11-03

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

30 enrolled